Search Site close Close
News

Clinical Study Seeks Participants with Lung Disease

Published Date:

Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that results in scarring (fibrosis) of the lungs for an unknown reason. Over time, the scarring gets worse and it becomes harder to take deep breaths. The lungs become unable to take in enough oxygen.

Dr. Rajagopal Sreedhar is recruiting participants for a clinical trial to see if pulmonary rehabilitation treatments improve the quality of life for patients with IPF. The study will compare standard of care treatment to exercise and education. The goal is test how well the combination of exercise and medication benefits the patient. All study-related visits and tests will be provided at no cost to the participant. Participants may also receive a stipend to cover travel and other related expenses.

To qualify, participants must:

  • Be 40 years of age or older
  • Have been diagnosed with IPF
  • Be currently taking the medication Ofev® (150 mg twice a day) and have taken it at a stable dose for up to 30 months

To learn more about this study, contact Abigail House, RN, at 217-545-7526.

More from SIU News

White Coat group Class of 2029

Class of 2029 - SIU School of Medicine

Student roster with hometowns & family, listed by region
COVID Stories Save the Dates

Audition to tell ‘COVID Stories’

University of Illinois Springfield and SIU School of Medicine are partnering to present "COVID Stories," a reader’s theater using real interviews about local Illinois residents’ pandemic experiences.
Dr. Ruchika Goel & Dr. O.H. Wesly

Dr. Ruchika Goel honored with endowed chair in hematologic disorders

Dr. Ruchika Goel is the inaugural recipient of the O.H. Wesly Endowed Chair of Excellence in Hematologic Disorders. The investiture ceremony on August 26 honored both Goel’s remarkable career as a physician-scientist and the enduring legacy of Dr. Wesly, whose generosity made the endowment possible.